Connect Biopharma Holdings Ltd (CNTB) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Connect Biopharma Holdings Ltd (CNTB) has a cash flow conversion efficiency ratio of -0.376x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-16.00 Million) by net assets ($42.62 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Connect Biopharma Holdings Ltd market capitalisation for the company's overall valuation and market capitalisation.
Connect Biopharma Holdings Ltd - Cash Flow Conversion Efficiency Trend (2018–2025)
This chart illustrates how Connect Biopharma Holdings Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Connect Biopharma Holdings Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Connect Biopharma Holdings Ltd ranked by their cash flow conversion efficiency. Explore cash flow quality index of Connect Biopharma Holdings Ltd to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Jaya Konstruksi Manggala Pratama
JK:JKON
|
-0.011x |
|
Ladprao General Hospital Public Company Limited
BK:LPH
|
0.077x |
|
AMCON Distributing Company
NYSE MKT:DIT
|
0.122x |
|
Netanel Group
TA:NTGR
|
0.010x |
|
Dwarikesh Sugar Industries Limited
NSE:DWARKESH
|
0.674x |
|
Blue Cap AG
XETRA:B7E
|
0.124x |
|
ArcelorMittal South Africa Limited
JSE:ACL
|
1.479x |
|
Pearl Holdings Acquisition Corp
NASDAQ:PRLH
|
0.003x |
Annual Cash Flow Conversion Efficiency for Connect Biopharma Holdings Ltd (2018–2025)
The table below shows the annual cash flow conversion efficiency of Connect Biopharma Holdings Ltd from 2018 to 2025. View CNTB stock price and chart for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $41.98 Million | $-51.21 Million | -1.220x | -376.12% |
| 2024-12-31 | $92.17 Million | $-23.61 Million | -0.256x | +45.75% |
| 2023-12-31 | $101.50 Million | $-47.93 Million | -0.472x | +25.08% |
| 2022-12-31 | $157.49 Million | $-99.27 Million | -0.630x | +68.51% |
| 2021-12-31 | $272.26 Million | $-544.93 Million | -2.002x | -287.84% |
| 2020-12-31 | $-24.03 Million | $-25.61 Million | 1.066x | -49.67% |
| 2019-12-31 | $-6.18 Million | $-13.09 Million | 2.117x | -40.46% |
| 2018-12-31 | $-19.41 Million | $-69.03 Million | 3.556x | -- |
About Connect Biopharma Holdings Ltd
Connect Biopharma Holdings Limited operates as a clinical-stage biopharmaceutical company in the United States. It develops rademikibart, a human monoclonal IgG4 antibody directed against IL-4Ra in two Phase 2 trials for the treatment of acute exacerbations of asthma and chronic obstructive pulmonary disease (COPD). The company was founded in 2012 and is headquartered in San Diego, California.